RRC ID 68100
著者 Panaampon J, Kariya R, Okada S.
タイトル Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
ジャーナル Cancer Immunol Immunother
Abstract Primary effusion lymphoma (PEL) is a rare, aggressive B cell non-Hodgkin's lymphoma of the body cavities with malignant effusions. The prognosis is poor, and no optimal treatment has been established. CD38 is a type II transmembrane glycoprotein known to overexpress in multiple myeloma (MM). Daratumumab (DARA), a human CD38-targeting monoclonal antibody (mAb), is approved for MM treatment. In this study, we found expression of CD38 on PEL cells and assessed the anti-PEL activity of DARA. We found that both KHYG-1 and N6 (CD16-transfected KHYG-1) NK cell lines showed direct killing activity against PEL cells with induction of CD107a, and NK-mediated cytotoxicity by N6NK (CD16+) cells increased with DARA treatment. We confirmed direct NK activity and antibody-dependent cell cytotoxicity (ADCC) by expanded NK cells, indicating that DARA has high ADCC activity. We elucidated the antibody-dependent cell phagocytosis (ADCP) by using human monocyte-derived macrophages (MDMs) and mouse peritoneal macrophages. DARA also showed potent complement-dependent cytolysis (CDC) toward PEL. DARA also induced PEL cell death in the presence of a cross-linking antibody. Moreover, treatment with DARA inhibited tumor growth in a PEL xenograft mouse model. These results provide preclinical evidence that Ab targeting of CD38 could be an effective therapeutic strategy for the treatment of PEL.
巻・号 71(5)
ページ 1017-1031
公開日 2022-5-1
DOI 10.1007/s00262-021-03054-8
PII 10.1007/s00262-021-03054-8
PMID 34545416
MeSH ADP-ribosyl Cyclase 1 Animals Antibodies, Monoclonal / pharmacology Antibodies, Monoclonal / therapeutic use Antibody-Dependent Cell Cytotoxicity Antineoplastic Agents* / therapeutic use Humans Lymphoma, Primary Effusion* / drug therapy Mice Multiple Myeloma*
IF 5.442
リソース情報
ヒト・動物細胞 K562